RecruitingAdvanced Adenocarcinoma
Phase 1 Study Evaluating BA3182 in Patients With Advanced Adenocarcinoma.
Eligible age
18+ yrs
Accepts
All genders
Locations
6 states
Healthy volunteers
No
See if you qualify for this study
Answer a few quick questions about your location and health. Takes about a minute.
About this study
The objective of this study is to assess safety and efficacy of BA3182 in Advanced Adenocarcinoma
Sponsor: BioAtla, Inc.
You may qualify if…
- ✓ Histologically or cytologically confirmed locally advanced unresectable or metastatic adenocarcinoma
- ✓ Age ≥ 18 years
- ✓ Adequate renal function
- ✓ Adequate liver function
- ✓ Adequate hematological function
- ✓ Have an Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1.
You may not qualify if…
- ✕ Patients must not have clinically significant cardiac disease.
- ✕ Patients must not have known non-controlled CNS metastasis.
- ✕ Patients must not have active autoimmune disease or a documented history of autoimmune disease.
- ✕ Patients must not have a history of ≥ Grade 3 allergic reactions to mAb therapy as wellas known or suspected allergy or intolerance to any agent given during this study.
- ✕ Patients must not incomplete recovery from the effects of major surgery or significant traumatic injury before the first dose of study treatment.
- ✕ Patients must not have known human immunodeficiency virus (HIV) infection, active hepatitis B and/or hepatitis C.
- ✕ Patients must not be women who are pregnant or breast feeding.
Where it's recruiting
California
Irvine · Los Angeles
Connecticut
New Haven
Illinois
Chicago
Michigan
Detroit
Ohio
Cincinnati · Cleveland
Washington
Seattle
Source: ClinicalTrials.gov · NCT05808634 · last updated 2025-09-25